Firstly, we determined whether the MDM2 inhibitor idasanutlin depends on wildtype p53 for its activity in ALL using an isogenic relapsed NALM6 cell line model with wildtype and monoallelic/biallelic TP53 deletion (Supplementary Fig. S1A). This evidence concerns the gene MDM2 and acute lymphoblastic leukemia.